Vancouver, BC / ACCESSWIRE / June 23, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC Pink: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that its wholly-owned subsidiary, BioCell Laboratories, Inc. ("BioCell"), was awarded an International Patent for refining the optimum natural sources of nitric oxide in the human body.
"Our International Patent signifies the groundbreaking nature of our discovery," said BioCell Laboratories, Inc. advisor, Brazos G. Minshew. "We are on the cusp of creating real-world solutions to the tragedies of our times. Nitric Oxide regulation holds the key to managing conditions from heart to brain to immune system function. Everyone benefits from Nitric Oxide "NO" balance; everyone needs these products."
Nitric Oxide is known as the "molecule of the millennium" in popular literature, with medical applications in fertility, sports performance, memory, sexual function, blood circulation, blood pressure, and immune function. About 100 years after Alfred Nobel patented Nitroglycerine for use in heart, brain, and immune system disorders, Ferid Murad and others received the Nobel Prize in Medicine for discovering the key component in nitroglycerine - Nitric Oxide.
"Abattis and BioCell plan to develop, patent, and market over three dozen products that are firmly grounded in the science underpinning the regulation of Nitric Oxide in the human body," said Abattis Bioceuticals Corp. President & CEO Mike Withrow.
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.
ON BEHALF OF THE BOARD
Michael Withrow, President & CEO
For further information, contact the Company's CEO, Michael Withrow at (778) 896-6536 or at email@example.com.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe", "plan" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
SOURCE: Abattis Bioceuticals Corp.